Head-to-head evidence
Linagliptin vs Sitagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Linagliptin · Tradjenta
Marketed by Boehringer Ingelheim and partners
NCT00602472 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 1,058 participants, and its primary endpoint was met: adjusted HbA1c change was −0.72% with linagliptin versus −0.10% with placebo (p<0.0001). The evidence is considered moderate because HbA1c is a surrogate measure rather than a hard clinical endpoint.
Sitagliptin · Januvia
Marketed by Merck & Co.
NCT00087516 · Phase 3 · completed
The trial randomized 741 participants to double-blind sitagliptin or placebo groups, providing a substantial controlled comparison. The primary endpoint, change in A1C at week 24, was statistically favorable for both sitagliptin doses (p<0.001), but A1C is a surrogate endpoint, so the evidence is rated moderate rather than strong.
Next expected readout: October 2026 · NCT07711171 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Linagliptin's landscape · Sitagliptin's landscape